circGFRA1 Enhances NSCLC Progression by Sponging miR-188-3p.

BACKGROUND: Lung cancer continues to be one of the most dangerous tumors around the world. It is an urgency to explore the molecular mechanism of non-small cell lung cancer (NSCLC) progression for developing novel therapeutic approaches. Circular RNA (circRNA) is a novel type of non-coding RNA with a stable closed loop structure. Abnormally expressed circRNAs have been found in many kinds of cancer including NSCLC. METHODS AND
RESULTS: The expression of circGFRA1 and miR-188-3p was detected in NSCLC tissues by RT-qPCR and it was found that circGFRA1 was highly expressed and miR-183-3p was lowly expressed in NSCLC tissues. In NSCLC cell lines, we confirmed that circGFRA1 acted as an miR-188-3p sponge using dual-luciferase reporter assay and RNA immunoprecipitation (RIP) analysis. Overexpression of cirGFRA1 enhanced NSCLC progression while miR-188-3p overexpression inhibited it by CCK8 and colony formation analysis. In vivo tumor xenograft model, circGFRA1 and miR-188-3p synergistically regulated the proliferation of NSCLC tumors. Mechanistic study indicated that circGFRA1 and miR-188-3p regulated the proliferation of NSCLC cells at least through PI3K/AKT signaling pathway.
CONCLUSION: Our study elaborated a novel circGFRA-miR-188-3p-PI3K/AKT regulatory pathway, providing a potential diagnostic biomarker and therapeutic target for NSCLC.

Introduction

Lung cancer continues to be one of the most dangerous tumors around the world. According to biological characteristics, lung cancer can be divided into two categories: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).1 NSCLC accounts for approximately 85% in lung cancer cases while the rest 15% belongs to SCLC.2 Since it is asymptomatic at the early stages, up to 61% of lung cancers are diagnosed at late stages.3 As cancer progresses from early stage to late stage, the survival rate decreases dramatically.3 The 5-year relative survival rate for NSCLC for all stages is only about 20%, while the survival rate declines to 4% at late stage.3 The molecular mechanism underlying NSCLC progression needs further exploration for developing novel therapeutic approaches.

Circular RNA is a novel type of non-coding RNA with a stable closed loop structure through a typical 5′ to 3′-phosphodiester bond.4 Although circRNAs are originally thought to be abnormal splicing products of RNA, accumulating evidence indicated that circRNAs are involved in various biological pathways including acting as miRNA sponge to inhibit the expression of miRNA, regulating RNA binding protein and nuclear transcription.5 Abnormally expressed circRNAs have been found in many kinds of cancer including NSCLC.6,7 Yao et al reported that the expression of circRNA 100876 was closely related to the carcinogenesis of NSCLC.8 Tian et al reported that circABCB10 could facilitate the proliferation and migration of NSCLC through sponging miR-1252.9 Wei et al found that circPTPRA could suppress epithelial-mesenchymal transformation and metastasis of NSCLC cells by sponging miR-96-5p.10 CircGFRA1 is a recently identified cancer-related circRNA. He et al found that circGFRA1 level was significantly upregulated in triple negative breast cancer cell lines through a circRNA microarray analysis.11 Liu et al reported that circGFRA1 promotes ovarian cancer progression by regulating miR-449a.12 However, the role of circGFRA1 in NSCLC progression is unclear.

MiRNAs are another class of endogenous non-coding RNAs with a length of about 22 nucleotides, which can negatively regulate gene expression through targeting to the 3ʹ-untranslated region (UTR) of the target mRNAs.13 Many miRNAs have been found to play important role in the development and progression of NSCLC. Qi et al found that miR-448 could target SIRT1 (Sirtuin 1) and promote progression of NSCLC.14 Tu et al found that miR-34c could inhibit the development of NSCLC by inducing endoplasmic reticulum stress through targeting HMGB1 (High Mobility Group Box 1).15 Xu et al reported that the expression of miR-155 and miR-21 was associated with the recurrence or metastasis of NSCLC.16 MiR-188-3p has been reported to be a tumor suppressor in several cancers, including hepatocellular carcinoma,17 breast cancer,18 colorectal cancer,19 and pancreatic cancer.20 However, the function of miR-188-3p in NSCLC still remains unexplored.

In this study, we detected the expression of circGFRA1 and miR-188-3p in NSCLC tissues and found that circGFRA1 expression was higher and miR-183-3p expression was lower in NSCLC tissues compared to that in normal adjacent tissues. In NSCLC cell lines, circGFRA1 and miR-183-3p could regulate the expression of each other. Overexpression of cirGFRA1 enhanced the development of NSCLC while miR-143-3p overexpression inhibited it both in vitro and in vivo. Further study indicated that circGFRA1 and miR-188-3p may act through PI3K/AKT signaling pathway to regulate the proliferation of NSCLC cells. Our study elaborated a novel circGFRA1-miR-188-3p-PI3K/AKT regulatory pathway, providing a potential diagnostic biomarker and therapeutic target for NSCLC.

Materials and Methods

Tissue Samples

NSCLC tumor tissues and normal adjacent tissues were obtained from 30 patients who have had surgery at Second Affiliated Hospital of Zhejiang University. A part of tissues was used for hematoxylin-eosin staining (HE staining), and the rest of tissues were rapidly frozen in liquid nitrogen and stored at −80°C preparing for RNA extraction. This study was approved by the Ethics Committee of Second Affiliated Hospital of Zhejiang University. Written informed consent was provided by all patients whose tissue samples were used. And the study was carried out in accordance with the principles of the Declaration of Helsinki.

Histology

Tissue samples were firstly fixed with 4% paraformaldehyde. Then, they were dehydrated, embedded, and sliced. The slices were stained using classical HE staining.

RT-qPCR Analysis

Total RNA of tissues or cells was extracted by TRNzol (TianGen, Beijing, China). For circRNA detection, total RNA was firstly digested by Rnase R to get rid of linear RNA, then cDNAs were synthesized with random primers. For miRNA, specific primer miRNA-RT was used for the reverse transcription of cDNA. Quantitative real-time PCR was conducted to detect the expression of circRNA and mRNA with GAPDH as an internal control. U6 was used as an internal control for detecting the expression of miRNA. The primer sequences were provided in .

Cell Culture

Human NSCLC cell lines (A549 and NCI-H838) were purchased from Tongpai biotechnology company (Shanghai, China). Both cell lines were cultured in RPMI 1640 medium (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37°C in an incubator with 5% CO2.

Cell Transfection

Negative control siRNA, si-GFRA1, miR-188-3p mimic and inhibitor were designed and synthesized by GenePharma (Shanghai, China). The sequences of circGFRA1 were cloned into the pcDNA3.1 by Sangon Biotech (Shang Hai, China). The pmirGLO luciferase vectors of circGFRA1 containing wild-type (WT) or mutated sequence in the putative miR-188-3p binding site (Mut) were also constructed by Sangon Biotech (Shang Hai, China), and named as pGLO-circGFRA1-WT and pGLO-circGFRA1-MUT separately. A549 or NCI-H838 cells were plated and transfected with siRNA, miRNA mimic and inhibitor, plasmids using lipofectamine 2000 (Invitrogen, USA) according to the manufacturer’s instruction. The sequences of siRNA were shown in .

Western Blot

Tissues or cells were harvested and lysed with RIPA Lysis Buffer (Beyotime Biotechnology, Beijing, China). The protein lysates were quantified and then separated by 8% SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis). Then, the proteins were transferred to polyvinylidenedifluoride membrane (Millipore, Billerica, USA). The membranes were blocked in 5% non-fat dry milk and incubated with primary antibodies at 4°C overnight, including Cyclin A1 (1:1000, ab53699, Abcam), Cyclin B1 (1:1000, ab72, Abcam), GAPDH (1:2000, 2118S, CST). Then, HRP-conjugated secondary antibodies were incubated for 1 h at room temperature. Finally, the bands were visualized by Tanon 5200.

Dual-Luciferase Reporter Assay

A549 and NCI-H838 cells were seeded and transfected with pGLO-circGFRA1-WT or pGLO-circGFRA1-MUT plasmid, together with miR-188-3p mimic or inhibitor. Cells were harvested 24 h later, luciferase activity was measured by the Dual-Luciferase Reporter Assay System (Promega Corp, Madison, WI, USA).

Cell Proliferation and Colony Formation Analysis

A549 or NCI-H838 cells were seeded in 24-well culture plates and transfected with relevant plasmids and siRNAs or treated with a PI3K pathway inhibitor-LY264002 for the indicated time-points. CCK-8 (Beyotime, Beijing, China) was used to perform the cell proliferation analysis according to the manufacturer’s instructions. For colony-forming analysis, circGFRA1 plasmid and miRNA mimic were transfected, respectively, or jointly into A549 or NCI-H838 cells. The transfected cells were seeded into twelve-well plates (600 cells/wells). Colonies were fixed by 4% paraformaldehyde 14 days later, and stained by 0.4% crystal violet solution. Colonies with diameter over 0.5 mm were counted under a light microscope.

RNA Immunoprecipitation (RIP)

Magna RIPTM RNA Binding Protein Immunoprecipitation Kit (Millipore, Bedford, MA, USA) was used to perform the RIP experiments in SPCA-1 and A549 cells. Samples obtained by RIP were digested by protease K and RNA was isolated for the detection of circGFRA1.

In vivo Tumor Xenograft Model

The NCI-H838 cells were transfected with pcDNA/Mock, circGFRA1/miR-188-3p or pcDNA/miR-188-3p for 72 h, then 1× 107 transfected cells were injected subcutaneously into BALB/c nude mice (6–7 weeks old, Weitonglihua, Beijing, China). The tumor size in all nude mice was measured every 3 days. All mice were sacrificed 18 days later following inoculation. Tumors were weighed, photographed, and frozen for reserved for RT-qPCR and Western blot analysis. The experimental procedures were guaranteed by the Guidelines for Care and Use of Laboratory Animal with approval of Ethics Committee of Zhejiang University.

Statistical Analysis

All statistical analysis was performed using SPSS 22.0 (IBM, SPSS, Chicago, IL, USA) with Student’s t-test and one-way ANOVA to estimate the significant group differences. Data were expressed as the mean ± S.E.M. (standard error of mean). P values < 0.05 were considered statistically significant.

Results

circGFRA1 Was Highly Expressed and miR-188-3p Was Lowly Expressed in NSCLC Tissues

NSCLC and normal adjacent tissues were obtained from 30 patients. The pathological changes of lung tissue were detected by HE staining and shown in Figure 1A.

Figure 1

CircGFRA1 was highly expressed and miR-143-3p was lowly expressed in NSCLC tissues. (A) The pathological changes of NSCLC tissues were detected by HE staining. (B) The expression of circGFRA1 in NSCLC and adjacent tissues was detected by RT-qPCR, #p<0.01 compared with adjacent tissues. (C) The expression of miR-188-3p in NSCLC and adjacent tissues was detected by RT-qPCR, #p<0.01 compared with adjacent tissues. (D) The correlation analysis of circGFRA1 and miR-188-3p levels in 30 NSCLC tissues.

The expression of circGFRA1 and miR-188-3p in NSCLC and adjacent tissues was detected by RT-qPCR. As shown in Figure 1B and C, the expression of circGFRA1 was up-regulated and miR-188-3p expression was down-regulated in NSCLC tissues compared with adjacent tissues. Pearson correlation analysis was subsequently performed and the result displayed an inverse correlation between circGFRA1 and miR-188-3p (Figure 1D). These results indicated that circGFRA1 and miR-188-3p might play an important role in NSCLC pathogenesis.

circGFRA1 Acted as a ceRNA to Sponge miR-188-3p

The “competing endogenous RNA (ceRNA) hypothesis” has been raised and validated by a plenty of studies.21 Many circRNAs have been found to act as ceRNAs to sequestrate target miRNAs. To investigate whether circGFRA1 could sponge miR-188-3p, we first predicted the binding site for circGFRA1 in miR-188-3p using miRcode online website (Figure 2A). Then, we determined whether miR-188-3p overexpression or knockdown could affect the expression of circGFRA1. As shown in Figure 2B, miR-188-3p was successfully over-expressed or knocked down through transfecting miR-188-3p or anti-miR-188-3p mimics in A549 and NCI-H838 cells. The expression of circGFRA1 was also detected by RT-qPCR, and the results demonstrated that miR-188-3p overexpression inhibited the expression of circGFRA1 while miR-188-3p knockdown promoted the expression (Figure 2C). To further validate the association between circGFRA1 and miR-188-3p, circGFRA1 binding sites wild type or mutated luciferase plasmids (termed as pGLO-circGFRA1-WT or pGLO-circGFRA1-MUT) were constructed (the sequence information is shown in Figure 2A), and luciferase activity was detected after pGLO-circGFRA1-WT or pGLO-circGFRA1-MUT was co-transfected with NC or si-circGFRA1 into A549 or NCI-H838 cells. As Figure 2D showed, compared with NC, si-circGFRA1 significantly reduced the luciferase activity when it was co-transfected with pGLO-circGFRA1-WT; however, the effects were absent when pGLO-circGFRA1-MUT plasmid was co-transfected with si-circGFRA1. The luciferase plasmids were also co-transfected with miR-188-3p or anti-miR-188-3p in A549 or NCI-H838 cells. As Figure 2E and F showed, miR-188-3p significantly reduced the luciferase activity when it was co-transfected with pGLO-circGFRA1-WT while anti-miR-188-3p promoted the activity. The effects were also absent when pGLO-circGFRA1-MUT plasmid was co-transfected. RIP analysis was performed to evaluate the enrichment of circGFRA1 and miR-188-3p by Ago2 antibody in A549 cells. The results further validated the binding between LINC00667 and miR-143-3p (Figure 2G).

Figure 2

CircGFRA1 acted as a ceRNA to sponge miR-188-3p. (A) The predicted binding site and mutant site for circGFRA1 in miR-188-3p. (B) RT-qPCR was performed to detect overexpression and knockdown efficiency of miR-188-3p in A549 or NCI-H838 cells, #P < 0.01 compared with Mock. (C) The expression of circGFRA1 was detected by RT-qPCR after miR-188-3p was overexpressed or knocked down in A549 or NCI-H838 cells. #P < 0.01 compared with Mock. (D) Luciferase activity was detected after pGLO-circGFRA1-WT or pGLO-circGFRA1-MUT was co-transfected with NC or si-circGFRA1 in A549 or NCI-H838 cells. #P < 0.01 compared with NC. (E and F) Luciferase activity was detected after pGLO-circGFRA1-WT or pGLO-circGFRA1-MUT was co-transfected with miR-188-3p or anti-miR-188-3p in A549 or NCI-H838 cells. #P < 0.01 compared with NC. (G) RIP analysis was used to evaluate the enrichment degree of circGFRA1 and miR-188-3p by Ago2 antibody in A549 cells. #P < 0.01 compared with IgG.

circGFRA1 and miR-188-3p Synergistically Regulated the Proliferation of NSCLC Cells

To study the function of circGFRA1 and miR-188-3p in NSCLC cells, circGFRA1 and miR-188-3p overexpression plasmids were constructed. The expression of circGFRA1 or miR-188-3p was significantly increased after being transfected into A549 or NCI-H838 cells, respectively, which indicated the overexpression efficiency (Figure 3A and B). Then, CCK8 assays were performed to determine the proliferation ability when circGFRA1 and miR-188-3p were transfected individually or jointly. As shown in Figure 3C and D, circGFRA1 overexpression significantly promoted the growth of A549 and NCI-H838 cells while miR-188-3p overexpression significantly inhibited it, and the pro- or anti-proliferation effects were absent when both circGFRA1 and miR-188-3p were overexpressed. circGFRA1 overexpression also increased the colony formation ability of A549 and NCI-H838 cells while miR-188-3p overexpression significantly inhibited it, and the pro- or anti-proliferation effect was absent when both circGFRA1 and miR-188-3p were overexpressed (Figure 3E and F). The expression of proliferation-related genes including Cyclin A1, Cyclin B1 was detected by western-blot. The results indicated that these genes were up-regulated when circGFRA1 was overexpressed; however, miR-188-3p overexpression inhibited the expression of these genes (Figure 3G–J). These results indicate that the circGFRA1/miR-188-3p axis regulates the growth of NSCLC cells, cooperatively.

Figure 3

The proliferation of NSCLC cells is regulated by circGFRA1 and miR-188-3p. (A and B) RT-qPCR was used to detect transfection efficiency of circGFRA1 or miR-188-3p in A549 and NCI-H838 cells. (C and D) Cell proliferation was determined by CCK-8 when circGFRA1 and miR-188-3p was transfected individually or jointly, #P < 0.01 compared with pcDNA/Mock, ΨP < 0.01 compared with circGFRA1/miR-188-3p. (E and F) Colony formation ability was evaluated in A549 and NCI-H838 cells when circGFRA1 and miR-188-3p was transfected individually or jointly, #P < 0.01 compared with pcDNA/Mock, ΨP < 0.01 compared with circGFRA1/miR-188-3p. (G, H, I, J) The expression of proliferation-related genes including Cyclin A1, Cyclin B1 was detected by western-blot and RT-qPCR in A549 and NCI-H838 cells. #P < 0.01 compared with pcDNA/Mock, ΨP < 0.01 compared with circGFRA1/miR-188-3p.

CircGFRA1 and miR-188-3p Synergistically Regulated the Proliferation of NSCLC Tumors in vivo

To explore the impact of the circGFRA1/miR-188-3p axis on tumorigenesis of NSCLC in vivo, NCI-H838 cells were transfected with pcDNA/Mock, circGFRA1/miR-188-3p or pcDNA/miR-188-3p and injected subcutaneously into BALB/c nude mice. Tumor volume was markedly decreased in pcDNA/miR-188-3p group when compared to pcDNA/Mock or circGFRA1/miR-188-3p group (Figure 4A). Representative images of resected tumor masses in each group were shown in Figure 4B. Tumor weight was also markedly decreased in pcDNA/miR-188-3p group when compared to pcDNA/Mock or circGFRA1/miR-188-3p group (Figure 4C). The expression of proliferation-related genes including Cyclin A1, Cyclin B1 was detected by Western blot. As shown in Figure 4D and E, miR-188-3p overexpression significantly inhibited the expression of Cyclin A1 and Cyclin B1, while circGFRA1 overexpression inhibited it. The expression of Cyclin A1 and Cyclin B1 was also detected by RT-qPCR, and a consistent result was obtained (Figure 4F). We also explored whether circGFRA1 knockdown could inhibit the proliferation of NSCLC tumors in vivo. Compared with the control, sh-circGFRA1 transfection significantly inhibited the growth of tumor. Tumor volume and weight were markedly decreased (). The mRNA expression of Cyclin A1 and Cyclin B1 was significantly inhibited when circGFRA1 expression was inhibited ().

Figure 4

circGFRA1 and miR-188-3p synergistically regulated the proliferation of NSCLC cells in vivo. The NCI-H838 cells were transfected with pcDNA/Mock, circGFRA1/miR-188-3p or pcDNA/miR-188-3p for 72 h, then the cells were inocubated subcutaneously into nude mice. (A) Tumor volume was markedly decreased in pcDNA/miR-188-3p when compared to pcDNA/Mock or circGFRA1/miR-188-3p group. #P < 0.01 compared with pcDNA/Mock, ΨP < 0.01 compared with circGFRA1/miR-188-3p. (B) Representative images of resected tumor masses in pcDNA/Mock, circGFRA1/miR-188-3p or pcDNA/miR-188-3p group. (C) Tumor weight was markedly decreased in pcDNA/miR-188-3p when compared to pcDNA/Mock or circGFRA1/miR-188-3p group. #P < 0.01 compared with pcDNA/Mock, ΨP < 0.01 compared with circGFRA1/miR-188-3p. (D and E) The expression of proliferation-related genes including Cyclin A1, Cyclin B1 was detected by western-blot, #P < 0.01 compared with pcDNA/Mock, ΨP < 0.01 compared with circGFRA1/miR-188-3p. (F) The expression of proliferation-related genes including Cyclin A1, Cyclin B1 was detected by RT-qPCR, #P < 0.01 compared with pcDNA/Mock, ΨP < 0.01 compared with circGFRA1/miR-188-3p.

circGFRA1/miR-188-3p May Regulate the Proliferation of NSCLC Cells Through the PI3K/AKT Signaling Pathway

PI3K/AKT signalling pathway plays an important role in tumor progression.22 We explored whether the circGFRA1/miR-188-3p axis regulated the development of NSCLC through PI3K/AKT signaling pathway. A549 and NCI-H838 cells transfected with circGFRA1 or pcDNA were treated with a classical PI3K inhibitor-LY264002 or DMSO, and the cell proliferation was detected by CCK8 assay. As shown in Figure 5A and B, LY264002 reversed the proliferative effect of circGFRA1. And LY264002 reversed the enhanced colony formation ability induced by circGFRA1 overexpression (Figure 5C). The expression of proliferation-related genes including Cyclin A1, Cyclin B1 was also detected by RT-qPCR in A549 and NCI-H838 cells. The result indicated that LY264002 reversed the upregulated expression of Cyclin A1 and Cyclin B1 caused by circGFRA1 overexpression (Figure 5D and E). A549 and NCI-H838 cells were also treated with anti-miR-188-3p and LY264002 individually or jointly. CCK8 analysis was also performed to evaluate the proliferation. As Figure 5F and G showed, anti-miR-188-3p significantly promoted the growth of A549 and NCI-H838 cells, this effect was reversed by LY264002. Additionally, LY264002 reversed the enhanced colony formation ability mediated by anti-miR-188-3p (Figure 5H). LY264002 rescued the upregulated expression of Cyclin A1 and Cyclin B1 caused by anti-miR-188-3p (Figure 5I and J). We also detected the phosphorylation level of AKT which plays a central role in the activation of PI3K/AKT signal. As shown in , overexpression of circGFRA1 significantly increases the phosphorylation level of AKT. However, PI3K/AKT inhibitor LY294002 reduced the increased phosphorylation level of AKT caused by circGFRA1 overexpression. The results further revealed that circGFRA1/miR-188-3p may regulate the proliferation of NSCLC cells through PI3K/AKT signal. These results indicate that the circGFRA1/miR-188-3p axis may regulate the proliferation of NSCLC cells through the PI3K/AKT signaling pathway.

Figure 5

circGFRA1 and miR-188-3p synergistically regulated the proliferation of NSCLC cells through the PI3K/AKT signaling pathway. (A and B) A549 and NCI-H838 cell proliferation was detected by CCK-8 assay after circGFRA1 and LY264002 was given individually or jointly. #P < 0.01 compared with pcDNA/DMSO, ΨP < 0.01 compared with circGFRA1/DMSO. (C) Colony formation ability was evaluated in A549 and NCI-H838 cells after circGFRA1 and LY264002 was given individually or jointly. #P < 0.01 compared with pcDNA/DMSO, ΨP < 0.01 compared with circGFRA1/DMSO. (D and E) The expression of proliferation-related genes including Cyclin A1, Cyclin B1 was detected by RT-qPCR, #P < 0.01 compared with pcDNA/DMSO, ΨP < 0.01 compared with circGFRA1/DMSO. (F and G) A549 and NCI-H838 cell proliferation was detected by CCK-8 assay after anti-miR-188-3p and LY264002 was given individually or jointly. #P < 0.01 compared with pcDNA/DMSO, ΨP < 0.01 compared with circGFRA1/DMSO. (H) Colony formation ability was evaluated in A549 and NCI-H838 cells after anti-miR-188-3p and LY264002 was given individually or jointly. #P < 0.01 compared with pcDNA/DMSO, ΨP < 0.01 compared with circGFRA1/DMSO. (I and J) The expression of proliferation-related genes including Cyclin A1, Cyclin B1 was detected by RT-qPCR, #P < 0.01 compared with pcDNA/DMSO, ΨP < 0.01 compared with circGFRA1/DMSO.

Discussion

NSCLC is one of the most common cancers with a low cure rate. Despite great efforts, the underlying mechanism of NSCLC tumorigenesis still remains to be fully elucidated.3 According to the research in recent years, ncRNAs including circRNA and miRNA are extensively involved in various biological processes.23 Increased evidence suggested that an aberrant expression of ncRNAs was associated with human diseases including cancer.24 In the past couple of years, several circRNAs have been found to act as important tumor suppressors or promote tumorigenesis in NSCLC.9,10 In the present study, we detected the expression of circGFRA1 and miR-188-3p in NSCLC tissues and found that the expression of circGFRA1 was negatively correlated with the expression of miR-188-3p. The expression of circGFRA1 was relatively high while miR-188-3p expression was low in NSCLC tissues. The increased expression of circGFRA1 in NSCLC tissues was consistent with the recently reported data in ovarian cancer and breast cancer.11,12 miR-188-3p has been found to be down-regulated in many kinds of tumors such as pancreatic cancer, hepatocellular carcinoma, and so on.17,20

Emerging evidence reveals that circRNAs can act as a ceRNA to sponge miRNAs. We then predicted that circGFRA1 could bind with miR-188-3p. The expression of circGFRA1 was down-regulated when miR-188-3p was overexpressed. The association between cirGFRA1 and miR-188-3p was further validated by dual-luciferase reporter and RIP analysis. These results revealed that circGFRA1 acts as an miR-188-3p sponge.

We next explore the function of cicGFRA1 and miR-188-3p in the tumor tumorigenesis. In vitro, we found circGFRA1 overexpression significantly promoted the growth of A549 and NCI-H838 cells and increased the expression of proliferation-related genes; however, miR-188-3p overexpression reversed these effect led by circGFRA1. These results revealed that the function of circGFRA1 and microRNA are antagonistic to each other. In vivo, we constructed tumor xenograft model and found a same trend with that in vitro. circGFRA1 overexpression promoted the development of NSCLC tumor, which was attenuated by miR-188-3p overexpression.

The PI3K/AKT signalling pathway is a classical oncogenic signalling pathway. Several ncRNAs have been found to regulate tumorigenesis through regulating the PI3K/AKT signalling pathway.25,26 In the present study, we used an inhibitor of PI3K/AKT and found that inhibition of PI3K/AKT signalling pathway could reverse the effects of cirGFRA1 and anti-miR-188-3p. These results imply that the cirGFRA1/miR-188-3p axis may act through PI3K/AKT signalling pathway to inhibit NSCLC progression. It is interesting to further explore the direct target that is regulated by the cirGFRA1/miR-188-3p axis in PI3K/AKT signalling pathway.

In conclusion, our study revealed that a novel cirGFRA1-miR-188-3p-PI3K/AKT axis playing an important role in the tumorigenesis of NSCLC. cirGFRA1 acts as a ceRNA to regulate the PI3K/AKT signalling pathway through sponging miR-188-3p. cirGFRA1 and miR-188-3p might be potential diagnostic biomarker and therapeutic targets for NSCLC.